Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dangerous Clutter: FDA Takes On Errors Caused By Drug Labels, Packaging

Executive Summary

Reducing the amount of unnecessary information on drug labels is one of several key ways to stop dangerous medication errors, a panel that is helping FDA develop guidance on the subject agreed

You may also be interested in...



Container Labels Expose Two Sides Of Color: Attention Getter, Lure To Medication Errors

FDA draft guidance lays out how sponsors can design drug container labels and carton labeling to avoid drug use mistakes by making the most important information accessible to health care providers and patients.

PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown

The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.

PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown

The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel